Literature DB >> 11078154

Comparison of the anti-Ro/SSA autoantibody profile between patients with primary and secondary Sjögren's syndrome.

I Gál1, G Lakos, M Zeher.   

Abstract

OBJECTIVE: To measure serum levels of anti-Ro52-kD/SSA, anti-Ro60-kD/SSA and anti-La/SSB autoantibodies in patients with primary and secondary Sjögren's syndrome. To examine if there is any connection between the disease and the subtype-spectrum of these antibodies.
METHODS: We measured serum levels of anti-Ro52-kD/SSA, anti-Ro60-kD/SSA and anti-La/SSB autoantibodies by ELISA, in the sera of patients with primary Sjögren's syndrome with or without extraglandular manifestations and with or without anti-La/SSB positivity and of patients with systemic lupus erythematosus/Sjögren's syndrome overlapping disease with or without anti-La/SSB positivity.
RESULTS: Differences of the distribution of the anti-Ro52-kD/SSA and the anti-Ro60-kD/SSA were found between the primary and secondary Sjögren's syndrome patients' groups; when Sjögren's syndrome is accompanied by systemic lupus erythematosus, the occurrence of anti-Ro60-kD/SSA autoantibodies is significantly higher than in primary Sjögren'syndrome.
CONCLUSION: Our results suggest that there is a possible connection between the distribution of the subtypes of the anti-Ro/SSA autoantibodies and the disease type in primary/secondary Sjögren's syndrome.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11078154     DOI: 10.3109/08916930008994077

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  4 in total

1.  Ultrastructure of myoepithelial cells as a target cell in sialoadenitis of submandibular glands of lupus-prone female NZBxNZWF1 mice.

Authors:  Toshiharu Hayashi; Hideyuki Hayashi; Taeko Fujii; Chie Adachi; Keiko Hasegawa
Journal:  Virchows Arch       Date:  2008-06-19       Impact factor: 4.064

Review 2.  A review of the role and clinical utility of anti-Ro52/TRIM21 in systemic autoimmunity.

Authors:  Adrian Y S Lee
Journal:  Rheumatol Int       Date:  2017-04-17       Impact factor: 2.631

3.  The prevalence and the clinical relevance of anti-Ro52 in Korean patients with primary Sjögren's syndrome.

Authors:  Jung-Soo Song; Jae Hyuk Do; Sang-Won Lee
Journal:  Rheumatol Int       Date:  2011-01-19       Impact factor: 2.631

4.  Diagnostic Utility of Separate Anti-Ro60 and Anti-Ro52/TRIM21 Antibody Detection in Autoimmune Diseases.

Authors:  Ailsa Robbins; Maxime Hentzien; Segolene Toquet; Kevin Didier; Amelie Servettaz; Bach-Nga Pham; Delphine Giusti
Journal:  Front Immunol       Date:  2019-03-12       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.